Population Pharmacokinetics/Pharmacodynamics of Carbapenems in Febrile Neutropenia Patients

Inclusion Criteria: Age ≥18 years old, regardless of gender; Patients with malignant hematological diseases with neutropenia and fever are judged as high-risk patients according to the Guidelines for Clinical Application of Antibiotics in Patients with Neutropenia and Fever in China (2020 Edition); There is infection, and the results of drug sensitivity test show that pathogenic bacteria are sensitive to meropenem or meropenem is used according to experience; The blood concentration of meropenem has reached a steady state; Each patient's blood sample points ≥2, and cases with only one blood sample point can also be included in the database; Sign the informed consent form. Exclusion Criteria: Patients with non-malignant hematological diseases; Non-granular deficiency with fever; Those who did not reach steady state when receiving meropenem; There is a history of meropenem drug allergy; The patient lacks treatment compliance based on the patient's history and the judgment of the researcher; The patient has hemophagocytic syndrome; Patients undergoing renal replacement therapy; Patients with incomplete clinical evaluation data (such as lack of information on renal function and biochemical indicators, and inability to obtain blood samples); The sample contains components that interfere with the determination of drug concentration (such as valproic acid and chloramphenicol); Pregnant and lactating women; Cases considered by the researcher as unsuitable for inclusion.